With just under two weeks till the festival, it’s time to start thinking logistics. The more scatter-brained of our readers needn’t worry, however: we’ve got everything you need covered in this handy guide, whether it’s things to remember before you arrive at the festival, the best things to do once there and the last couple of things to remember when it’s all done.
Genetics Unzipped, a new fortnightly podcast from the UK Genetics Society, has launched ahead of the society’s centenary celebrations throughout 2019. Presented by award-winning science writer and former Naked Genetics/Naked Scientists podcast host Kat Arney and produced by First Create The Media, Genetics Unzipped will bring you a wide range of stories from the world of genetics, genomics and DNA.
SOPHiA GENETICS has successfully completed a $77 million funding round, the company recently announced at the JP Morgan Healthcare Conference in San Francisco.
A Boston biotechnology company has built a neural network which examines the overall elements of the human face and compiles a list of the ten genetic syndromes that person potentially has, possibly helping medical professionals narrow down the diagnosis for that individual.
The first results of the BabySeq Project, a study to determine whether deep dives into infant DNA could uncover more diseases, and whether making this procedure routine after childbirth would be worth it, have been published.
A new AI program can predict the symptoms of a patient’s cancer and their severity of the course of treatment.
A CRISPR study has determined how DNA times its own replication, something which until now has been unknown to scientists.
Data has shown the success of a new therapy to combat Leber congenital amaurosis (LCA), one of the leading causes of blindness in children, in LCA patients with CEP290 mutations. CEP290 acts as a barrier between two compartments of photoreceptor cells in the eye which convert light into signals, creating vision. Blindnesses caused by CEP290 […]
Researchers have announced that tetrahydrocannabinol (THC), an active ingredient in marijuana, affects epigenetics, triggering structural and regulatory changes in the DNA of users’ sperm.
Telbivudine, a drug currently in use for treating patients with hepatitis, could be of use in significantly slowing the progression of Amyotrophic lateral sclerosis (ALS), scientists from the University of Alberta have announced.
A new compound which blocks the most common genetic cause of familial ALS has been announced by scientists from the University of Alberta.
Eleven new genes associated with epilepsy have been discovered by an international team of scientists, advancing knowledge of the underlying causes of the condition and potentially helping in the development of new treatments.
Personalised tumour-detecting cells from adult skin cells have been used to shrink brain tumours in mice by up to 5%, scientists have revealed. While the strategy has not yet been fully tested in people, it could in the future give doctors the ability to develop a custom treatment for certain cancer types.
Amgen and Entera Bio are partnering up to develop new treatments for inflammatory disease and certain other serious illnesses using the Entera drug discovery program. The platform will be used to develop oral formulations for one preclinical large molecule program which Amgen has selected. Entera’s CEO said the collaboration would be an important validation test of the platform technology.
Scientists from the University of Pennsylvania have created a test using gene-editing tools such as CRISPR to identify a gene variant responsible for severe hypertrophic cardiomyopathy (SHC). SHC is an often-familial disease which thickens heart walls and is linked to a variant in the TNNT2 gene.
